KasraKaramlouMD

Hematology • Avon, OH

Physician

Join to view full profile

Dr. Karamlou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karamlou's full profile

Already have an account?

Office
Cleveland Clinic - Avon Hospital at Richard E. Jacobs Campus
33100 Cleveland Clinic Blvd
Avon, OH 44011
Phone+1 419-626-9090

Fax+1 480-854-6769

Summary

Dr. Kasra Karamlou is an oncologist in Avon, OH and is affiliated with Cleveland Clinic. He received his medical degree from George Washington University School of Medicine and has been in practice 21 years. He also speaks multiple languages, including Farsi. He is experienced in esophageal cancer, colorectal cancer, amyloidosis, chemotherapy, and hematologic oncology. He has 5 publications and over 150 citings.

Education & Training

Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 1999 - 2003
Baylor College of MedicineResidency, Internal Medicine, 1996 - 1999
George Washington University School of Medicine and Health SciencesClass of 1996

Certifications & Licensure

OR State Medical License 2000 - Present
OH State Medical License 2018 - 2026
CA State Medical License 2012 - 2022
AZ State Medical License 2016 - 2019
WA State Medical License 2005 - 2013
TX State Medical License 1998 - 2000
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2014

Clinical Trials

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2008 Feb 29
Active, not recruiting
Phase 3
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer Start of enrollment: 2018 Mar 27
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Case report: multiple gastrointestinal stroma tumors in the background of neurofibromatosis type 1.
Tim N. Beck, Kevin Brown, James Lapinski, Ram Gurajala, Kasra Karamlou
Journal of Surgical Case Reports. 2020-12-01
47 citations
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study
Guillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, Bruno C. Medeiros, Martha Arellano
Blood Advances. 2019-02-26
104 citations
Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective.
Jennifer R. Garreau, Tammy DeLaMelena, Deb Walts, Kasra Karamlou, Nathalie Johnson
American Journal of Surgery. 2006-10-01

Press Mentions

Phase 2 Study of Duvelisib in Previously Treated Patients with Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (BRIO)December 12th, 2017

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member

Other Languages

Farsi